Clinical Biorepository Core

摘要 这种PPG应用的总体前提是，在开发中存在共享的生物学途径， COPD和IPF。为了进一步了解COPD的流行病学、生物学和遗传学特征， IPF（肺对常见有害暴露（如烟草烟雾）的不同反应） 汇总和整理来自多个现有COPD和IPF队列的数据，并创建一个新的Brone- 结肠镜检查队列。该临床生物储备库核心将为所有共同研究提供统一的标准数据集。 调查人员在这项申请中。这些数据将包括临床、流行病学、生理学和放射学亚组， 分型信息以及将用于横截面和纵向分析的生物样本。 为了实现这些目标，临床生物储备核心汇集了国际公认的 研究者团队，其专业知识涵盖临床研究、放射学评估和支气管镜检查 问题研究这项研究所利用的现有队列包括三个NIH资助的项目， COPDGene，SPIROMICS和肺组织研究联盟（LTRC），每个都有丰富的 表型数据将用于疾病亚型。该核心还将利用一个基金会资助的 肺纤维化基金会临床护理登记和生物储存库（PFF）。最后 前瞻性支气管镜检查人群将包括40例既往吸烟的COPD受试者（20例肺气肿 主要疾病和20例气道主要疾病），30例既往吸烟者IPF（15例典型UIP和15例 可能/不一致的UIP）和20名年龄和性别匹配的对照（均为戒烟者）。

ABSTRACT The overall premise of this PPG application is that there are shared biologic pathways in the development of COPD and IPF. To further understand the epidemiologic, biologic, and genetic characteristics of COPD and IPF (divergent pulmonary response to common noxious exposures such as tobacco smoke) we are proposing to aggregate and curate data from several existing COPD and IPF cohorts as well as create a de-novo bron- choscopy cohort. This Clinical Biorepository Core will provide a harmonized standard dataset for all co- investigators in this application. These data will include clinical, epidemiologic, physiologic and radiologic sub- typing information as well as biospecimens which will be used for cross sectional and longitudinal analyses. To achieve these goals, the Clinical Biorepository Core has brought together an internationally recognized team of investigators whose expertise spans clinical investigation, radiologic assessments and bronchoscopic studies. The existing cohorts to be leveraged by this investigation include three NIH funded projects, COPDGene, SPIROMICS and the Lung Tissue Research Consortium (LTRC), each of which has a wealth of phenotypic data that will be leveraged for disease subtyping. This Core will also leverage a foundation funded effort called the Pulmonary Fibrosis Foundation Clinical Care Registry and Biorepository (PFF). Finally, the prospective Bronchoscopy Population will include 40 ex-smoking subjects with COPD (20 with emphysema predominant and 20 with airway predominant disease), 30 ex-smokers with IPF (15 with Typical UIP and 15 with probable/inconsistent UIP) and 20 age and sex matched controls (all ex-smokers).